Monitor mid-2026 for Cohort 1 dystrophin data, which will be the first efficacy readout for ENTR-601-45. Positive dystrophin expression could drive significant upside for this single-asset-stage biotech; negative or ambiguous data would be highly bearish. Until then, no near-term catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $6.64entry
- T+1 · 6mo ago −0.90%α −0.18% · $6.58
- T+5 · 5mo ago −4.07%α −1.10% · $6.37
- T+20 · 5mo ago +14.31%α +15.87% · $7.59
- T+60 · 3mo ago +5.42%α +4.30% · $7.00
Price Chart
How similar events traded
Executive Summary
Entrada Therapeutics announced that an independent DMC recommended dose escalation to 10 mg/kg in Cohort 2 of the ELEVATE-45-201 Phase 1/2 study for ENTR-601-45 in Duchenne muscular dystrophy (exon 45). The company remains on track to report Cohort 1 safety, PK, and dystrophin data in mid-2026, with Cohort 2 and 3 data to follow. This is a routine clinical progress update with no new efficacy data released, making the near-term impact neutral.
Key Facts
- DMC recommended initiation of Cohort 2 at 10 mg/kg (up from 5 mg/kg in Cohort 1) after reviewing safety and PK data from 8 participants.
- Company on track to report Cohort 1 data (safety, early PK, dystrophin) in mid-2026.
- ELEVATE-45-201 is a Phase 1/2 MAD study of ENTR-601-45 for DMD patients amenable to exon 45 skipping.
- Dosing regimen is once every six weeks; planned doses across three cohorts range from 5 mg/kg to 15 mg/kg.
- No financial data, revenue, or earnings were disclosed in the press release.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage biotech.
Risk Factors
- Cohort 1 data (mid-2026) may show insufficient dystrophin expression or safety signals, leading to program termination.
- DMD exon 45 space is competitive (Sarepta's Casimersen already approved); differentiation on efficacy or dosing frequency is unproven.
- Pre-revenue company with limited cash runway, future dilution risk for ongoing trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304981 |
Track record
21 reports on TRDA
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +58.22% at T+20 after the May 4, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $4.55 Now $5.00 +9.89% settles Feb 3
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $4.55 Now $5.00 +9.89% settles Jan 11
- Sep 9, 20269w ago Insider Cluster Bearish 6/10 Entry $6.42 Now $5.00 +22.12% settles Dec 4
- Sep 3, 202610w ago Insider Cluster Neutral 3/10 Entry $7.13 Now $5.00 −29.87% settles Dec 1
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 3/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $7.27 Now $5.00 −31.22% settles Nov 20
- Aug 10, 202614w ago Insider Cluster Neutral 2/10 Entry $7.04 to $5.06 Now $5.00 −28.98% ▼ −28.13% −27.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers